Elamipretide (SS-31): Mitochondrial Targeting Peptide Research

elamipretide is a synthetic, mitochondria-targeted tetrapeptide first studied in academic mitochondrial-biology laboratories and now the active molecule of the FDA-approved brand forzinity. Under the code names ss-31, MTP-131 and Bendavia it accumulated two decades of preclinical literature before its first accelerated approval in 2025. This page is the molecule-level root of this site: structure, mechanism, trials, safety and market, each summarized here and expanded in its own cluster page.

The scope is deliberately academic. We compile what published data demonstrates about the peptide — binding constants where reported, trial endpoints where they exist, catalog prices where they are public — and we do not extend any of it into medical advice or acquisition guidance. The brand-level view (approval record, label, cost, assistance) lives in the forzinity research pillar; the two pillars interlink throughout.

Most therapeutic peptides run 10–40 residues; elamipretide has four. The sequence is H-D-Arg–2',6'-Dmt–Lys–Phe-NH₂, where Dmt is 2',6'-dimethyltyrosine — a synthetically modified aromatic residue that replaces natural tyrosine. A C-terminal amide and one D-enantiomer residue round out a structure that no ribosome makes. Its small size and aromatic-cationic character give it the membrane-association behavior documented across the ss-31 literature — the full structural parameters are tabulated on our elamipretide structure page.

Calling it a “peptide” rather than a “small molecule” matters commercially as well as chemically: peptides are synthesized, not distilled; they carry counter-ions; their purity and identity are chromatography- and mass-spectrometry questions. Those properties explain both the research-grade market (catalog ss-31 priced per milligram) and why forzinity's manufacturing economics differ from classical small-molecule drugs — a point developed on the forzinity generic research page.

The published parameters: molecular formula C₃₂H₄₉N₉O₅, molecular weight approximately 639.8 Da (free base), a net positive charge at physiological pH from its arginine, lysine and N-terminal amine, and hydrophobic bulk concentrated in the dimethylated aromatic residue. Research suggests this exact combination — cationic for electrostatic attraction to anionic membranes, aromatic for tight binding — is what the original screening selected for.

For researchers, structure has practical consequences: the peptide is soluble, lyophilizes well, and — per label documentation — shows a plasma half-life around 4 hours while its membrane-associated residence behaves differently, a decoupling repeatedly noted in the pharmacokinetic literature. The structure page carries the full table with sources and the reasoning behind each parameter.

Published data demonstrates that elamipretide associates with cardiolipin, the anionic phospholipid unique to the inner mitochondrial membrane, and that this association measurably changes membrane properties: cristae morphology, electron-transport-chain supercomplex organization, and reactive-oxygen-species production under stress. Studies show ongoing research potential in ischemia-reperfusion, aging-muscle and cardiolipin-deficiency models. The mechanistic chain — binding, membrane stabilization, downstream bioenergetics — is laid out with its evidence tiers on our mechanism of action page.

The intellectual center of the program is specificity: mitochondria are the only organelles whose membranes are rich in cardiolipin, so a cardiolipin-binding cationic peptide is effectively a targeting device. That elegance also explains the mixed clinical record — where the underlying membrane is defective (Barth syndrome), research suggests the intervention has its clearest signal; where the disease is multifactorial (heart failure, AMD), the same trials investigated without confirming benefit. Our clinical trials pillar holds that record.

One molecule, six names, three channels. The academic name ss-31 comes from screening-library numbering; MTP-131 and Bendavia are development-stage names; elamipretide is the generic (INN) name; forzinity is the approved U.S. brand; 2S50 is a research-catalog designation used in the research-supply market. Search volume splits across all of them, which is why this site maintains a dedicated forzinity and elamipretide name-mapping page.

The naming also encodes regulatory status, which is why we are precise about it: a search for “ss-31 peptide” mostly reaches the research channel, while “forzinity” reaches the pharmaceutical channel — and the two channels answer to entirely different regulators, documents and price systems. The forzinity vs ss-31 and forzinity vs 2S50 pages compare them parameter by parameter.

Before the first human trials, the ss-31 literature accumulated animal-model work across ischemia-reperfusion injury, aging skeletal muscle, and cardiac bioenergetics — a body of work repeatedly cited as the rationale for the clinical programs that followed. Published data demonstrates mitochondrial membrane effects across these models, with effect sizes that motivated the step into humans. We treat this literature as background context for the trial record rather than as evidence about any human outcome.

For research-literacy purposes, the preclinical record also documents what the peptide does not do: it is not an antioxidant in the classical sense, not a coenzyme-Q mimic, and not an uncoupler — categories a reader will meet in secondary summaries that blur them. Our evidence-graded summaries distinguish mechanism claims by tier per the editorial policy.

elamipretide's clinical record now spans four therapeutic areas: Barth syndrome (TAZPOWER, leading to the 2025 accelerated approval of forzinity), primary mitochondrial myopathy (MMPOWER-3), heart failure (PROGRESS-HF), and dry age-related macular degeneration (ReCLAIM). One approval, several missed primary endpoints elsewhere — a genuinely mixed record that we document endpoint by endpoint in the clinical trials pillar, with per-area pages for heart failure and AMD.

The molecule-level lesson researchers draw from that pattern — that membrane-stabilization signals may require a membrane defect to reach significance — remains an interpretation, and we mark it as one. What is data: the approved indication research base, the label parameters summarized in the forzinity pillar, and the dosing and administration data on the forzinity dosage data page.

Across trials and the approved label, elamipretide's tolerability profile is dominated by local injection-site events: erythema, pain and pruritus at frequencies documented on our elamipretide side effects page and its brand-level counterpart, the forzinity safety overview. A laboratory signal — eosinophilia with extended exposure — appears in the label and is dissected on the eosinophilia research page. Mechanistic work on MRGPRX2, a mast-cell receptor implicated in some peptide injection reactions, connects the clinical observation to peptide chemistry on the injection-site reactions page.

We present these as data with sources: frequencies by population, onset timing where reported, monitoring language where the label carries it. No page on this site interprets safety data into individual risk statements — that is what the label, clinicians and regulators are for.

Parallel to the pharmaceutical channel, a research-supply market sells ss-31-labeled elamipretide for laboratory use, at catalog prices typically in the tens of pounds per 10 mg — documented with sources and dates on our elamipretide cost page. That market exists for a legitimate reason (labs need the peptide for the kind of research summarized above) and is governed by research-use-only terms that our elamipretide peptide buy market-trends page analyzes as an industry structure — with no purchase guidance and no links to sellers.

Searches in Portuguese (comprar, preço, para que serve) overlap heavily with this market cluster; we cover that demand within the market and uses pages rather than creating thin translated pages, so the analysis stays consolidated and the content stays deep.

The three-step discipline applies molecule-wide. Extract: every elamipretide figure with its source, date and measurement method — a binding constant from a 2010 biophysics paper and a 2025 label frequency are different kinds of numbers. Normalize: trial percentages by population; catalog prices by milligram and salt form; half-lives by compartment measured. Grade: regulatory documents and peer-reviewed work outrank aggregators and forums — the full hierarchy is in our editorial policy.

Because elamipretide spans six names and two markets, one extra rule: always confirm which name — and therefore which channel — a source is describing before citing it. Half the confusion in this field is channel confusion wearing a chemistry costume.

From this pillar: structure and mechanism pages (structure, mechanism), regulatory pages (fda approval research), research applications (uses, clinical trials pillar), safety (side effects data) and market pages (cost, market trends).

The brand-level cluster — label, dosage data, assistance, coupons, label, website, generic — hangs from the forzinity pillar; pricing and access research from the cost pillar. All three pillars interlink, and every subpage links back to its pillar: a strict hub-and-spoke topology built for topic authority.